{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:09:39Z","timestamp":1785434979795,"version":"3.56.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"BARDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.vaccine.2021.02.007","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T16:03:22Z","timestamp":1612886602000},"page":"2791-2799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":214,"title":["A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8950-6117","authenticated-orcid":false,"given":"Laurence","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick","family":"McPhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenmei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamilton","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Pajon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biliana","family":"Nestorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0907-0817","authenticated-orcid":false,"given":"Brett","family":"Leav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.02.007_b0005","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2021.02.007_b0010","unstructured":"WHO. WHO Coronavirus Disease (COVID-19) Dashboard. November 9, 2020. https:\/\/covid19.who.int\/?gclid=CjwKCAjwps75BRAcEiwAEiACMVdInLBoj_EeG7jJA_kaMRM93bsTUDSzJE8Qb7Z2C2Em4mlzqLkEKxoCH54QAvD_BwE."},{"key":"10.1016\/j.vaccine.2021.02.007_b0015","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","author":"Viruses. CSGotICoTo","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2021.02.007_b0020","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.02.007_b0025","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Thanh Le","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2021.02.007_b0030","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 Vaccines at Pandemic Speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.02.007_b0035","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0140-6736(20)32137-1","article-title":"SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates","volume":"396","author":"Poland","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.02.007_b0040","unstructured":"Society RAP. COVID Vaccine tracker; 2020."},{"key":"10.1016\/j.vaccine.2021.02.007_b0045","article-title":"Will covid-19 vaccines save lives? Current trials aren't designed to tell us","volume":"371","author":"Doshi","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2021.02.007_b0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","article-title":"The promise of mRNA vaccines: a biotech and industrial perspective","volume":"5","author":"Jackson","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2021.02.007_b0055","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2021.02.007_b0060","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.007_b0065","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.02.007_b0070","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cell.2017.03.016","article-title":"Modified mRNA Vaccines Protect against Zika Virus Infection","volume":"169","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2021.02.007_b0075","unstructured":"Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Stud. 2020."},{"key":"10.1016\/j.vaccine.2021.02.007_b0080","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2 - Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.02.007_b0085","article-title":"RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study","author":"Walsh","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.vaccine.2021.02.007_b0090","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2021.02.007_b0095","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.02.007_b0100","first-page":"1","article-title":"A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults","author":"Aliprantis","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.02.007_b0105","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","author":"Baden","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.02.007_b0110","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.02.007_b0115","article-title":"SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness","author":"Corbett","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.vaccine.2021.02.007_b0120","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.02.007_b0125","article-title":"Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination","author":"Widge","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.02.007_b0130","unstructured":"ACCELERATED EMERGENCY USE AUTHORIZATION (EUA) SUMMARY SARS-CoV-2 RT-PCR TEST (Viracor Eurofins Clinical Diagnostics). 2020."},{"key":"10.1016\/j.vaccine.2021.02.007_b0135","unstructured":"Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting. https:\/\/investor.lilly.com\/node\/43721\/pdf2020."},{"key":"10.1016\/j.vaccine.2021.02.007_b0140","unstructured":"Regeneron's Regn-Cov2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized Covid-19 Patients. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and2020."},{"key":"10.1016\/j.vaccine.2021.02.007_b0145","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.02.007_b0150","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2033700","article-title":"Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults","author":"Libster","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.02.007_b0155","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00281-020-00821-0","article-title":"Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population","volume":"42","author":"Ciabattini","year":"2020","journal-title":"Semin Immunopathol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21001535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21001535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:54:19Z","timestamp":1759402459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21001535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":31,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0264410X21001535"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.007","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Moderna Therapeutics. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}